Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
22.59
Oct 19 • 5:48 AM ET Dollar change-1.22 Percentage change(-5.12%)
Oct 16, 11:02 AMARK discloses $19M IAM buy as Nvidia-backed IPO extends rally 25% in session
Index
-
Market Cap
1.07B
Enterprise Value
-
Income
-
Sales
-
Book/sh
-
Cash/sh
-
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Oct 15, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
-
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
-
Insider Trans
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
3.77%
SMA50
3.77%
SMA200
3.77%
Trades
Shs Outstand
47.40M
Shs Float
35.70M
52W High
25.00 -9.64%
52W Low
16.15 39.88%
Volatility
- -
ATR (14)
4.37
RSI (14)
-
Beta
-
Rel Volume
0.17
Avg Volume
2.49M
Volume
21,515
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
Perf YTD
39.88%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
23.81
Price
22.59
Change %
-5.12%
Oct-16-26 01:46PM
Oct-15-26 01:38PM
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Co-FounderDr. Thomas Miller Ph.D.
Chief Corporate Development Officer & CFODr. Michael Secora Ph.D.
Chief Medical OfficerDr. Neil Josephson M.D.
Senior VP & Head of DiscoveryMr. Laurent Gomez Ph.D.
Senior Vice President of Machine LearningMr. Matt Welborn Ph.D.